Q&A: Page 4

Exclusive interviews with industry leaders

  • Teresa Bitetti, president, global oncology business unit, Takeda
    Image attribution tooltip
    Permission granted by Takeda
    Image attribution tooltip

    How Takeda finds the hottest new science to fuel its oncology work

    Takeda's president of the global oncology business unit is always "scanning the horizon" for the partnerships that will drive the next big innovations.

    Michael Gibney • June 1, 2023
  • young cow
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    From farm to pharma: How cows could play a role in the next flu breakthrough

    SAb Biotherapeutics is working on a novel product that uses cow antibodies genetically engineered into human antibodies to prevent and treat infectious diseases.

    Alexandra Pecci • May 16, 2023
  • Christopher Boone AbbVie
    Image attribution tooltip
    Permission granted by Christopher Boone AbbVie
    Image attribution tooltip

    AbbVie’s Christopher Boone on RWE’s potential — and its ‘profound ethical dilemmas’

    With decades of experience in public health, Boone is leveraging RWE to move the needle within clinical development.

    Taren Grom • May 10, 2023
  • Bahija Jallal Immunocore 2
    Image attribution tooltip
    Permission granted by Bahija Jallal
    Image attribution tooltip

    How Immunocore’s Bahija Jallal embraced the ‘a-ha’ moment of promising science

    The biotech CEO is bullish on the company’s pioneering T cell receptor platform and innovating new immunology-based treatments.

    Taren Grom • May 5, 2023
  • Martine van Vugt, executive vice president and chief strategy officer, Genmab
    Image attribution tooltip
    Permission granted by Genmab
    Image attribution tooltip

    From science to strategy, this exec is painting Genmab’s bigger picture into the next decade

    Martine van Vugt, recently named Genmab’s chief strategy officer and executive vice president, aims to usher in the company’s next wave of "knock your socks off" antibodies.

    Michael Gibney • May 2, 2023
  • Kurt Harrington bicycle
    Image attribution tooltip
    Permission granted by Kurt Harrington
    Image attribution tooltip

    A CEO’s quest to solve a 400-year-old medical mystery — and he’s also a patient

    The CEO of Ventoux Biosciences has the disease that his company is aiming to treat, and it's driving him to find better medications.

    Taren Grom • May 1, 2023
  • 5 minutes
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    5 minutes with — DTRA’s Dr. Amir Kalali

    An industry veteran, innovator and curator, Dr. Amir Kalali discusses the high points of his career and his go-to productivity hack.

    Taren Grom • April 28, 2023
  • Lou Tartaglia, founder and managing partner, Cure Ventures
    Image attribution tooltip
    Permission granted by Cure Ventures
    Image attribution tooltip

    Cure Ventures has $350M to pour deep into biotech ‘company building’

    The biotech venture capital firm Cure Ventures, led by three industry veterans, raised the inaugural fund in early April and will soon announce its seed companies.

    Michael Gibney • April 20, 2023
  • Chris Benecchi, chief business officer, Sage Therapeutics
    Image attribution tooltip
    Permission granted by Sage
    Image attribution tooltip

    Depression has long been treated chronically — Sage wants to change that

    Sage Therapeutics is planning a launch of its newest med, and its chief business officer explains how it could upend the way depression has long been treated.

    Michael Gibney • April 18, 2023
  • Awan Ahsan
    Image attribution tooltip
    Permission granted by Ahsan Awan
    Image attribution tooltip

    5 minutes with — Genlantis Diagnostics’ Ahsan Awan

    A serial entrepreneur, futurist and industry disrupter, the VP of clinical development and digital health is always on the quest to build a “better mousetrap.”

    Taren Grom • April 14, 2023
  • Peyton Howell Parexel
    Image attribution tooltip
    Permission granted by Peyton Howell
    Image attribution tooltip

    5 minutes with — Parexel’s Peyton Howell

    The company’s chief operating and growth officer on her personal quirks and why every pharma leader should read "Getting Naked."

    Taren Grom • April 7, 2023
  • cardio
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Amgen’s aim for a ‘moonshot’ in cardiovascular disease

    A VP of global development at Amgen explains how treating general medicine diseases could one day resemble approaches in oncology.  

    Taren Grom • April 5, 2023
  • Rich Christie, chief medical officer, AiCure
    Image attribution tooltip
    Permission granted by AiCure
    Image attribution tooltip

    Digital biomarkers lay the groundwork for precision medicine beyond the bloodwork

    Biomarkers are the hidden talent behind precision medicine, and finding them doesn't have to always come from a blood test — digital pioneers are finding another way.

    Michael Gibney • March 30, 2023
  • Mayank Anand, vice president and global head of data strategy and management, GSK
    Image attribution tooltip
    Permission granted by GSK
    Image attribution tooltip

    This GSK clinical data leader embraces the ‘Rubik’s cube’ problem: solving for all sides at once

    The clinical data space is rapidly changing the face of the industry, GSK's Mayank Anand said — and the way organizations adopt technology is a critical part of the equation.

    Michael Gibney • March 23, 2023
  • Babson Diagnostics
    Image attribution tooltip
    Permission granted by Babson Diagnostics
    Image attribution tooltip

    Babson aims to shed Theranos curse with new blood testing tech

    Babson Diagnostics is trying to create a less invasive blood testing technology — can it gain trust in the post-Theranos era?

    Kelly Bilodeau • March 13, 2023
  • Murray Aitken IQVIA Institute
    Image attribution tooltip
    Permission granted by Murray Aitken/IQVIA Institute
    Image attribution tooltip

    IQVIA’s OG of data analytics on the latest clinical trial trends

    IQVIA Institute’s Murray Aitken is the man behind the numbers, and here, shares the newest findings on clinical trial burnout, diversity and more.

    Taren Grom • March 10, 2023
  • Cooked vegetables in black plastic containers
    Image attribution tooltip
    Permission granted by Faeth
    Image attribution tooltip

    While many leverage precision medicine, Faeth is banking on precision nutrition to tackle cancer

    The San Francisco-based biotech is pairing metabolically-engineered diets with existing therapies to starve and kill tumors.

    Karissa Waddick • March 9, 2023
  • Cell therapy DNA
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    The ‘recovering academic’ leading Allogene to the next stage of cell therapy

    Zachary Roberts joined Allogene at the beginning of this year to lead the company's R&D and bring allogeneic cell therapy to the forefront.

    Michael Gibney • March 2, 2023
  • A 3D illustration of ribonucleic acid, or RNA, strands
    Image attribution tooltip
    Christoph Burgstedt via Getty Images
    Image attribution tooltip

    Launched with a ‘pioneer’ in RNA, aTyr Pharma is charting a new course in immunology

    With a focus on rare and hard-to-treat diseases, aTyr is banking on its head start in tRNA and vast IP portfolio to build a billion-dollar company.

    Taren Grom • March 2, 2023
  • Faby Malik Cytokinetics
    Image attribution tooltip
    Permission granted by Dr. Faby Malik, Cytokinetics
    Image attribution tooltip

    Cytokinetics looks to muscle into the cardiovascular market

    With a scientific platform based on muscle biology, the late-stage biotech is addressing cardiovascular and neuromuscular diseases.

    Taren Grom • Feb. 24, 2023
  • patient care
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Why patient care is a public affair

    The VP of public affairs at Kyowa Kirin discusses her role in advocating for advocacy.

    Taren Grom • Feb. 23, 2023
  • vaccine vial
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pheast’s new CEO on how its ‘don’t eat me’ platform could deliver next-gen precision immunotherapies

    Jacopo Leonardi’s latest venture is in the burgeoning field of macrophage inhibitors that could target a wide range of cancers.

    Taren Grom • Feb. 17, 2023
  • Cancer antibodies
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Nectin’s Keytruda combo could fill gaps in immuno-oncology’s treatment paradigm

    The Israeli biotech just entered into a collaboration with Merck to develop its own checkpoint inhibitor alongside the bestselling cancer treatment.

    Michael Gibney • Feb. 16, 2023
  • Will Chou headshot
    Image attribution tooltip
    Permission granted by Dr. William Chou, Passage Bio
    Image attribution tooltip

    Managing for resilience: Passage’s ups and downs in gene therapy

    After a rocky year, Passage Bio’s CEO is focused on helping the rare disease specialist bounce back.

    Meagan Parrish • Feb. 15, 2023
  • Professional headshot of Brian Fox
    Image attribution tooltip
    Permission granted by Klick Group
    Image attribution tooltip

    Brian Fox is bringing ‘fresh eyes’ to ad agency Klick

    Why the recently appointed president of commercial solutions sees near limitless potential to expand Klick’s footprint across the life sciences — and how generative AI is playing a role.

    Karissa Waddick • Feb. 13, 2023